




Instance: composition-en-7f1553dfd98eb10665faba03861da449
InstanceOf: CompositionUvEpi
Title: "Composition for kapruvia Package Leaflet"
Description:  "Composition for kapruvia Package Leaflet"
Usage: #inline

* identifier.system = "http://ema.europa.eu/identifier"

* identifier.value = "identifier"
* status = #final

* type = https://spor.ema.europa.eu/rmswi/#100000155538
* type.text = "Package Leaflet"

* subject = Reference(mp7f1553dfd98eb10665faba03861da449)
* date = "2022-02-16T13:28:17Z"

 

 // Reference to Organization: MAH
* author = Reference(mah-ema)


* title = "TEST PURPOSES ONLY - kapruvia"
* attester.mode = http://hl7.org/fhir/composition-attestation-mode#official
* attester.time =  "2022-02-16T13:28:17Z"
* language = #en
* category = epicategory-cs#R "Raw"


* section[+].
  * title = "B. Package Leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "B. Package Leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   


      
* section[=].section[+]
  * title = "Package leaflet: Information for the user"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "Package leaflet: Information for the user"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   



* section[=].section[+]
  * title = "What is in this leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "What is in this leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>What is in this leaflet</p>
<ol>
<li>What Kapruvia is and what it is used for  </li>
<li>What you need to know before you use Kapruvia  </li>
<li>How to use Kapruvia  </li>
<li>Possible side effects  </li>
<li>How to store Kapruvia </li>
<li>Contents of the pack and other information </li>
</ol>         </div>"""   
          

* section[=].section[+]
  * title =  "1. What kapruvia is and what it is used for"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text =  "1. What kapruvia is and what it is used for"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Kapruvia contains the active substance difelikefalin. It is used to treat itching in adults with chronic 
kidney disease who need dialysis to clean their blood. </p>
<p>Kapruvia works at targets in the body called kappa-opioid receptors which are involved in controlling 
the perception of itching. By stimulating these receptors on nerves and immune cells outside the brain, 
Kapruvia relieves the sensation of itch caused by chronic kidney disease. The active substance 
difelikefalin does not pass the blood-brain barrier (the natural protective barrier between blood vessels 
and the brain), which reduces the risk of side effects. </p>         </div>"""   
          

             
* section[=].section[+]
  * title = "2. What you need to know before you take kapruvia"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "2. What you need to know before you take kapruvia"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Do not use Kapruvia 
* if you are allergic to difelikefalin or any of the other ingredients of this medicine (listed in 
section 6). </p>
<p>Warnings and precautions<br />
Talk to your doctor or nurse before you are given Kapruvia if you: 
* have an increased potassium level in the blood 
* have or have had heart weakness or a heart rhythm disorder 
* have reduced function of the blood-brain barrier (such as cancer in the brain or the central 
nervous system, or a disease of the central nervous system like multiple sclerosis or dementia) 
as this might increase your risk of side effects 
* are 65 years of age or older, as you may be more likely to be made drowsy by the medicine 
* are using medicines that could increase the risk of drowsiness or dizziness, such as:</p>
<ul>
<li>medicines that slow down brain activity such as those that help with sleep disturbances 
and anxiety </li>
<li>medicines to treat allergies, cold, nausea and/or vomiting called sedating antihistamines  </li>
<li>strong painkillers, called opioid analgesics 
Talk to your doctor if you take any of these medicines. </li>
</ul>
<p>Children and adolescents 
Kapruvia is not recommended for children under 18 years, as it has not been studied in these patients. </p>
<p>Other medicines and Kapruvia 
Tell your doctor if you are using, have recently used or might use any other medicines. </p>
<p>Pregnancy and breast-feeding 
If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask 
your doctor for advice before you are given Kapruvia. </p>
<p>Kapruvia has not been studied in pregnant women. It is unknown whether Kapruvia can harm the 
unborn baby. Your doctor will discuss with you if you should use Kapruvia during pregnancy.  </p>
<p>It is not known whether difelikefalin can pass into breast milk. If you are breast-feeding your doctor 
will advise you on whether to stop breast-feeding or using Kapruvia, considering the benefit of breast-
feeding to the baby and Kapruvia to you, the mother.  </p>
<p>Driving and using machines 
Kapruvia can cause drowsiness and dizziness which may affect your ability to react. Do not drive or 
use machines if your ability to react is reduced or you do not know the effect of Kapruvia on your 
ability to react. </p>
<p>Kapruvia contains sodium 
This medicine contains less than 1 mmol sodium (23 mg) per vial, that is to say essentially  sodium-
free .  </p>         </div>"""   
                    
* section[=].section[+]
  * title =  "3. How to take kapruvia"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "3. How to take kapruvia"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>The doctor will work out the right dose of Kapruvia for you, based on your body weight. It will be 
given as an injection into a vein by a doctor or nurse at the end of your dialysis treatment through the 
tube that connects you to the dialysis machine. </p>
<p>Kapruvia will be given 3 times per week. This increases to 4 times per week in case of a fourth 
dialysis. No more than 4 doses are recommended, even if the number of dialysis treatments in a week 
is more than 4. If a dialysis treatment is unfinished, your doctor will decide whether it is better for you to receive 
Kapruvia after the unfinished dialysis session or wait until your next dialysis treatment. 
If a dialysis treatment is missed, the usual dose of Kapruvia will be given to you at the next dialysis 
treatment. 
Itching is expected to decrease after 2-3 weeks treatment with Kapruvia. </p>
<p>Patients with reduced liver function 
No dose adjustment is required for patients with mild or moderate reduced liver function. Kapruvia is 
not recommended for patients with severely reduced liver function, as use has not been studied in 
these patients. </p>
<p>If you have been given more Kapruvia than you should 
This increases the occurrence of side effects listed in section 4. Inform your doctor if you think this 
applies to you. </p>
<p>If you have any further questions on the use of this medicine, ask your doctor or nurse. </p>         </div>"""         

        
* section[=].section[+]
  * title = "4. Possible side effects"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "4. Possible side effects"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Like all medicines, this medicine can cause side effects, although not everybody gets them. </p>
<p>The following side effects have been reported in patients receiving this medicine: </p>
<p>Common, may affect up to 1 in 10 people: 
* drowsiness 
* sensation disorder in the skin such as tingling, prickling, burning or numbness, decreased 
feeling or sensitivity </p>
<p>Uncommon, may affect up to 1 in 100 people: 
* dizziness 
* headache 
* changes in mental status (alertness and clarity of thought), including confusion 
* nausea, vomiting 
* diarrhoea </p>
<p>Reporting of side effects 
If you get any side effects, talk to your doctor or nurse. This includes any possible side effects not 
listed in this leaflet. You can also report side effects directly via the national reporting system listed in 
Appendix V. By reporting side effects you can help provide more information on the safety of this 
medicine. </p>         </div>"""      
        
* section[=].section[+]
  * title = "5. How to store kapruvia"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "5. How to store kapruvia"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Keep this medicine out of the sight and reach of children. </p>
<p>Do not use this medicine after the expiry date which is stated on the label and carton after  EXP . The 
expiry date refers to the last day of that month. </p>
<p>This medicine does not require any special storage conditions. </p>         </div>"""      
        
        
* section[=].section[+]
  * title = "6. Contents of the pack and other information"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "6. Contents of the pack and other information"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>What Kapruvia contains<br />
* The active substance is difelikefalin. 
Each vial contains 50 micrograms of difelikefalin (as acetate) in 1.0 mL solution. 
* The other ingredients are acetic acid (for pH adjustment), sodium acetate trihydrate (for pH 
adjustment), sodium chloride, water for injections. See section 2  Kapruvia contains sodium . </p>
<p>What Kapruvia looks like and contents of the pack 
Kapruvia is a clear, colourless solution and free from particles (pH 4.5). It is supplied in a glass vial 
with rubber stopper, an aluminium seal and a blue flip-off plastic cap. </p>
<p>Pack sizes of 3 and 12 vials. </p>
<p>Not all pack sizes may be marketed. </p>
<p>Marketing Authorisation Holder 
Vifor Fresenius Medical Care Renal Pharma France 
100 101 Terrasse Boieldieu 
Tour Franklin La D fense 8 
92042 Paris La D fense Cedex 
France </p>
<p>Manufacturer 
Vifor France 
100 101 Terrasse Boieldieu 
Tour Franklin La D fense 8 
92042 Paris La D fense Cedex 
France </p>
<p>For any information about this medicine, please contact the Marketing Authorisation Holder. </p>
<p>This leaflet was last revised in </p>
<p>Detailed information on this medicine is available on the European Medicines Agency web site: </p>         </div>"""      



Instance: composition-da-7f1553dfd98eb10665faba03861da449
InstanceOf: CompositionUvEpi
Title: "Composition for kapruvia Package Leaflet"
Description:  "Composition for kapruvia Package Leaflet"
Usage: #inline

* identifier.system = "http://ema.europa.eu/identifier"

* identifier.value = "identifier"
* status = #final

* type = https://spor.ema.europa.eu/rmswi/#100000155538
* type.text = "Package Leaflet"

* subject = Reference(mp7f1553dfd98eb10665faba03861da449)
* date = "2022-02-16T13:28:17Z"

 

 // Reference to Organization: MAH
* author = Reference(mah-ema)


* title = "TEST PURPOSES ONLY - kapruvia"
* attester.mode = http://hl7.org/fhir/composition-attestation-mode#official
* attester.time =  "2022-02-16T13:28:17Z"
* language = #da
* category = epicategory-cs#R "Raw"


* section[+].
  * title = "B. Package Leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "B. Package Leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   


      
* section[=].section[+]
  * title = "Package leaflet: Information for the user"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "Package leaflet: Information for the user"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   



* section[=].section[+]
  * title = "What is in this leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "What is in this leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Oversigt over indlægssedlen </p>
<ol>
<li>Virkning og anvendelse </li>
<li>Det skal du vide, før du begynder at bruge Kapruvia </li>
<li>Sådan skal du bruge Kapruvia </li>
<li>Bivirkninger </li>
<li>Opbevaring </li>
<li>Pakningsstørrelser og yderligere oplysninger </li>
</ol>         </div>"""   
          

* section[=].section[+]
  * title =  "1. What kapruvia is and what it is used for"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text =  "1. What kapruvia is and what it is used for"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Kapruvia indeholder det aktive stof difelikefalin. Det bruges til at behandle kløe hos voksne med 
kronisk nyresygdom, som har behov for dialyse til at få renset blodet. </p>
<p>Kapruvia virker på steder i kroppen, som kaldes kappa-opioidreceptorer, som medvirker til at 
kontrollere opfattelsen af kløe. Ved at stimulere disse receptorer på nerver og immunceller uden for 
hjernen, lindrer Kapruvia følelsen af kløe, som skyldes kronisk nyresygdom. Det aktive stof, 
difelikefalin, passerer ikke blod-hjerne-barrieren (den naturlige beskyttende barriere mellem 
blodkarrene og hjernen), hvilket mindsker risikoen for bivirkninger. </p>         </div>"""   
          

             
* section[=].section[+]
  * title = "2. What you need to know before you take kapruvia"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "2. What you need to know before you take kapruvia"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Brug ikke Kapruvia </p>
<ul>
<li>hvis du er allergisk over for difelikefalin eller et af de øvrige indholdsstoffer i Kapruvia (angivet 
i punkt 6). </li>
</ul>
<p>Advarsler og forsigtighedsregler 
Kontakt lægen eller sygeplejersken, før du får Kapruvia, hvis du: </p>
<ul>
<li>
<p>har et forøget kalium-niveau i blodet </p>
</li>
<li>
<p>har eller har haft hjertesvigt eller en hjerterytmeforstyrrelse </p>
</li>
<li>
<p>har nedsat funktion af blod-hjerne-barrieren, (som f.eks. kræft i hjernen eller 
centralnervesystemet eller en sygdom i centralnervesystemet som multipel sklerose eller 
demens), da det kan øge risikoen for bivirkninger. </p>
</li>
<li>
<p>Er 65 år eller ældre, da du i så fald har større sandsynlighed for at blive døsig af medicinen </p>
</li>
</ul>
<h2>* bruger lægemidler, som kan øge risikoen for døsighed eller svimmelhed som f.eks.:</h2>
<p>lægemidler, der giver langsommere hjerneaktivitet, f.eks. lægemidler, der hjælper mod 
søvnforstyrrelser og angst 
- 
lægemidler til behandling af allergi, forkølelse, kvalme og/eller opkastning, som kaldes 
sederende (sløvende) antihistaminer 
- 
stærke smertestillende midler, kaldet opioide analgetika 
Tal med lægen, hvis du tager nogle af disse lægemidler. </p>
<p>Børn og unge 
Kapruvia anbefales ikke til børn under 18 år, da det ikke er undersøgt i denne patientgruppe. </p>
<p>Brug af anden medicin sammen med Kapruvia 
Fortæl lægen, hvis du bruger anden medicin, for nylig har brugt anden medicin eller planlægger at 
bruge anden medicin. </p>
<p>Graviditet og amning 
Hvis du er gravid eller ammer, har mistanke om, at du er gravid, eller planlægger at blive gravid, skal 
du spørge din læge til råds, før du får Kapruvia. </p>
<p>Kapruvia er ikke undersøgt hos gravide kvinder. Det vides ikke, om Kapruvia kan skade det ufødte 
barn. Din læge vil tale med dig om, hvorvidt du må bruge Kapruvia under graviditeten. </p>
<p>Det vides ikke, om difelikefalin kan blive udskilt i brystmælk. Hvis du ammer, vil din læge rådgive 
dig om, hvorvidt du skal holde op med at amme eller med at bruge Kapruvia, idet han eller hun afvejer 
fordele og ulemper ved Kapruvia for barnet og dig, moderen. </p>
<p>Trafik- og arbejdssikkerhed 
Kapruvia kan give døsighed og svimmelhed, som kan påvirke din reaktionsevne. Lad være med at 
køre bil eller betjene maskiner, hvis din reaktionsevne er nedsat, eller hvis du ikke kender Kapruvias 
virkning på din reaktionsevne. </p>
<p>Kapruvia indeholder natrium 
Dette lægemiddel indeholder mindre end 1 mmol (23 mg) natrium pr. hætteglas, dvs. det er i det 
væsentlige natriumfrit. </p>         </div>"""   
                    
* section[=].section[+]
  * title =  "3. How to take kapruvia"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "3. How to take kapruvia"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Lægen vil finde frem til den rigtige dosis af Kapruvia til dig ud fra din kropsvægt. Lægemidlet vil 
blive givet som en indsprøjtning i en vene af en læge eller sygeplejerske, når din dialysebehandling er 
slut, via den slange, som forbinder dig med dialysemaskinen. </p>
<p>Kapruvia vil blive givet 3 gange om ugen. Det stiger til 4 gange om ugen, hvis du skal have en fjerde 
dialysebehandling. Der må højst gives 4 doser i løbet af en uge, selvom du får mere end 
4 dialysebehandlinger. </p>
<p>Hvis en dialysebehandling ikke afsluttes, vil din læge beslutte, om det er bedst for dig at få Kapruvia 
efter den uafsluttede dialysebehandling eller vente til den næste dialysebehandling. 
Hvis en dialysebehandling springes over, vil du få den samme dosis Kapruvia ved den næste 
dialysebehandling. </p>
<p>Kløen forventes at mindskes efter 2-3 ugers behandling med Kapruvia. </p>
<p>Patienter med nedsat leverfunktion 
Dosisreduktion er ikke nødvendig hos patienter med mild eller moderat nedsat leverfunktion. Kapruvia 
anbefales ikke til patienter med svært nedsat leverfunktion, da det ikke er undersøgt i denne 
patientgruppe. </p>
<p>Hvis du har fået for meget Kapruvia 
Dette øger forekomsten af de bivirkninger, som er angivet i punkt 4. Informer lægen, hvis du mener, at 
det gælder for dig. </p>
<p>Spørg lægen eller sygeplejersken, hvis der er noget, du er i tvivl om. </p>         </div>"""         

        
* section[=].section[+]
  * title = "4. Possible side effects"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "4. Possible side effects"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Dette lægemiddel kan som alle andre lægemidler give bivirkninger, men ikke alle får bivirkninger. </p>
<p>Følgende bivirkninger er rapporteret hos patienter, der får dette lægemiddel: </p>
<p>Almindelige kan forekomme hos op til 1 ud af 10 personer: </p>
<ul>
<li>
<p>døsighed </p>
</li>
<li>
<p>føleforstyrrelse i huden som stikkende, prikkende eller brændende fornemmelse eller 
følelsesløshed, nedsat følelse eller følsomhed </p>
</li>
</ul>
<p>Ikke almindelige kan forekomme hos op til 1 ud af 100 personer: </p>
<ul>
<li>
<p>svimmelhed </p>
</li>
<li>
<p>hovedpine </p>
</li>
<li>
<p>ændringer i mental status (vågenhed og evne til at tænke klart), inkl. forvirring </p>
</li>
<li>
<p>kvalme, opkastning </p>
</li>
<li>
<p>diarré </p>
</li>
</ul>
<p>Indberetning af bivirkninger 
Hvis du oplever bivirkninger, bør du tale med din læge eller sygeplejersken. Dette gælder også mulige 
bivirkninger, som ikke er medtaget i denne indlægsseddel. Du eller dine pårørende kan også indberette 
bivirkninger direkte til Lægemiddelstyrelsen via det nationale rapporteringssystem anført i 
Appendiks V. Ved at indrapportere bivirkninger kan du hjælpe med at fremskaffe mere information 
om sikkerheden af dette lægemiddel. </p>         </div>"""      
        
* section[=].section[+]
  * title = "5. How to store kapruvia"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "5. How to store kapruvia"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Opbevar lægemidlet utilgængeligt for børn. </p>
<p>Brug ikke lægemidlet efter den udløbsdato, der står på etiketten og kartonen efter EXP. Udløbsdatoen 
er den sidste dag i den nævnte måned. </p>
<p>Dette lægemiddel kræver ingen særlige forholdsregler vedrørende opbevaringen. </p>         </div>"""      
        
        
* section[=].section[+]
  * title = "6. Contents of the pack and other information"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "6. Contents of the pack and other information"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Kapruvia indeholder: </p>
<ul>
<li>
<p>Aktivt stof: difelikefalin. 
Hvert hætteglas indeholder 50 mikrogram difelikefalin (som acetat) i 1.0 ml opløsning. </p>
</li>
<li>
<p>Øvrige indholdsstoffer: eddikesyre (til regulering af pH), natriumacetattrihydrat (til regulering 
af pH), natriumchlorid, vand til injektionsvæske. Se punkt 2 “Kapruvia indeholder natrium". </p>
</li>
</ul>
<p>Udseende og pakningsstørrelser 
Kapruvia er en klar, farveløs opløsning og fri for partikler (pH 4.5). Det leveres i hætteglas af glas med 
gummiprop, aluminiumsforsegling og blå flip-off-plastikhætte. </p>
<p>Pakningsstørrelser med 3 og 12 hætteglas. </p>
<p>Ikke alle pakningsstørrelser er nødvendigvis markedsført. </p>
<p>Indehaver af markedsføringstilladelsen og fremstiller 
Vifor Fresenius Medical Care Renal Pharma France 
100-101 Terrasse Boieldieu 
Tour Franklin La Défense 8 
92042 Paris La Défense Cedex 
Frankrig </p>
<p>Fremstiller 
Vifor France 
100-101 Terrasse Boieldieu 
Tour Franklin La Défense 8 
92042 Paris La Défense Cedex 
Frankrig </p>
<p>Hvis du ønsker yderligere oplysninger om dette lægemiddel, skal du henvende dig til den lokale 
repræsentant for indehaveren af markedsføringstilladelsen. </p>
<p>Denne indlægsseddel blev senest ændret </p>
<p>Du kan finde yderligere oplysninger om dette lægemiddel på Det Europæiske Lægemiddelagenturs 
hjemmeside: http://www.ema.europa.eu. </p>         </div>"""      





                    
Instance: bundlepackageleaflet-en-7f1553dfd98eb10665faba03861da449
InstanceOf: BundleUvEpi
Title: "ePI document Bundle for kapruvia Package Leaflet for language en"
Description: "ePI document Bundle for kapruvia Package Leaflet for language en"
Usage: #example


* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* type = #document
* timestamp = "2023-06-27T10:09:22Z"
* language = #en

// Composition
* entry[0].fullUrl = "Composition/composition-en-7f1553dfd98eb10665faba03861da449"
* entry[0].resource = composition-en-7f1553dfd98eb10665faba03861da449

// MPD
* entry[+].fullUrl = "MedicinalProductDefinition/mp7f1553dfd98eb10665faba03861da449"
* entry[=].resource = mp7f1553dfd98eb10665faba03861da449
                            
                    
Instance: bundlepackageleaflet-da-7f1553dfd98eb10665faba03861da449
InstanceOf: BundleUvEpi
Title: "ePI document Bundle for kapruvia Package Leaflet for language da"
Description: "ePI document Bundle for kapruvia Package Leaflet for language da"
Usage: #example


* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* type = #document
* timestamp = "2023-06-27T10:09:22Z"
* language = #da

// Composition
* entry[0].fullUrl = "Composition/composition-da-7f1553dfd98eb10665faba03861da449"
* entry[0].resource = composition-da-7f1553dfd98eb10665faba03861da449

// MPD
* entry[+].fullUrl = "MedicinalProductDefinition/mp7f1553dfd98eb10665faba03861da449"
* entry[=].resource = mp7f1553dfd98eb10665faba03861da449
                            
                    



Instance: mp7f1553dfd98eb10665faba03861da449
InstanceOf: MedicinalProductDefinitionUvEpi
Title: "Medicinal Product Kapruvia 50 micrograms/mL solution for injection"
Description: "Kapruvia 50 micrograms/mL solution for injection"
Usage: #inline

 
* identifier[+].system = "http://ema.europa.eu/identifier"
* identifier[=].value = "EU/1/22/1643/001"
* type = http://hl7.org/fhir/medicinal-product-type#MedicinalProduct "Medicinal Product"

* domain = http://hl7.org/fhir/medicinal-product-domain#Human "Human use"

* status = http://hl7.org/fhir/publication-status#active "active"



* legalStatusOfSupply = $spor-rms#100000072084 "Medicinal product subject to medical prescription"

* name
  * productName = "Kapruvia 50 micrograms/mL solution for injection"
  * type = $spor-productNamePartType-cs#220000000001 "Full name" 
  
  * part[0]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000002 "Invented name part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000003 "Scientific name part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000004 "Strength part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000005 "Pharmaceutical dose form part"
  
  * usage
    * country = urn:iso:std:iso:3166#EU "EU"
    * jurisdiction = urn:iso:std:iso:3166#EU "EU"
    * language = urn:ietf:bcp:47#en  "en"



RuleSet: 7f1553dfd98eb10665faba03861da449ListRuleset

* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* identifier[+].system = "http://spor.ema.europa.eu/v2/medicine-name"
* identifier[=].value = "kapruvia"

* status = #current
* mode = #working

* title = "List of all ePIs associated with kapruvia"

* subject = Reference(mp7f1553dfd98eb10665faba03861da449)
* subject.extension[0].url = "http://ema.europa.eu/fhir/extension/medicine-name"
* subject.extension[=].valueCoding = $100000000005#kapruvia "kapruvia"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/marketing-authorization-holder"
* subject.extension[=].valueCoding = $100000000005#mah-code "None"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/active-substance"
* subject.extension[=].valueCoding = $100000000005#acive-substance-code "None"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/domain"
* subject.extension[=].valueCoding = $100000000004#100000000012 "H"

* date = "2015-02-07T13:28:17Z"


* entry
  * flag = urn:oid:1.2.36.1.2001.1001.101.104.16592#01
  * flag.text = "Unchanged"
  * date = "2015-02-07T13:28:17Z"
  * item = Reference(bundlepackageleaflet-en-7f1553dfd98eb10665faba03861da449) // kapruvia en
  * item.extension[0].url = "http://ema.europa.eu/fhir/extension/documentType"
  * item.extension[=].valueCoding = $100000155531#100000155538 "B. PACKAGE LEAFLET"
  * item.extension[+].url = "http://ema.europa.eu/fhir/extension/language"
  * item.extension[=].valueCoding = $100000072057#100000072147 "en"



* entry
  * flag = urn:oid:1.2.36.1.2001.1001.101.104.16592#01
  * flag.text = "Unchanged"
  * date = "2015-02-07T13:28:17Z"
  * item = Reference(bundlepackageleaflet-da-7f1553dfd98eb10665faba03861da449) // kapruvia da
  * item.extension[0].url = "http://ema.europa.eu/fhir/extension/documentType"
  * item.extension[=].valueCoding = $100000155531#100000155538 "B. PACKAGE LEAFLET"
  * item.extension[+].url = "http://ema.europa.eu/fhir/extension/language"
  * item.extension[=].valueCoding = $100000072057#100000072147 "da"




Instance: List-7f1553dfd98eb10665faba03861da449
InstanceOf: List

* insert 7f1553dfd98eb10665faba03861da449ListRuleset
    